| 1 | treating | 11,234 |
| 2 | managing | 2,371 |
| 3 | rehabilitating | 29 |
| 4 | subacute/chronic | 21 |
| 5 | middle-third | 6 |
| 6 | immunising | 5 |
| 7 | 1,776 | 4 |
| 8 | d2-dissected | 4 |
| 9 | extubating | 4 |
| 10 | interferon-alpha-induced | 4 |
| 11 | young/middle-aged | 4 |
| 12 | 11,234 | 3 |
| 13 | ir-nmibc | 3 |
| 14 | nonremitted | 3 |
| 15 | pain-predominant | 3 |
| 16 | preventing/treating | 3 |
| 17 | sri-refractory | 3 |
| 18 | subclassifying | 3 |
| 19 | 15,847 | 2 |
| 20 | 2778 | 2 |
| 21 | 3,204 | 2 |
| 22 | 4,589 | 2 |
| 23 | 5,031 | 2 |
| 24 | 5474 | 2 |
| 25 | 7007 | 2 |
| 26 | anthracycline-naïve | 2 |
| 27 | anti-tnf-treated | 2 |
| 28 | caf-treated | 2 |
| 29 | endoscopy-refractory | 2 |
| 30 | flt3‑mutated | 2 |
| 31 | hs-fused | 2 |
| 32 | ifn-α-treated | 2 |
| 33 | in-the-field | 2 |
| 34 | infection-confirmed | 2 |
| 35 | mad-treated | 2 |
| 36 | mixed-beam-treated | 2 |
| 37 | multiple-drug-refractory | 2 |
| 38 | non-constipating | 2 |
| 39 | non-exacerbating | 2 |
| 40 | nonautoclaved | 2 |
| 41 | noninfection-related | 2 |
| 42 | perceivably | 2 |
| 43 | pneumovirus-induced | 2 |
| 44 | ppi-intolerant | 2 |
| 45 | salicylate-poisoned | 2 |
| 46 | sub-typing | 2 |
| 47 | subdysthymic | 2 |
| 48 | 1,958,716 | 1 |
| 49 | 11,774 | 1 |
| 50 | 116/137 | 1 |
| 51 | 12,507 | 1 |
| 52 | 12,930 | 1 |
| 53 | 13,627 | 1 |
| 54 | 13107 | 1 |
| 55 | 14,209 | 1 |
| 56 | 14,754 | 1 |
| 57 | 146,961 | 1 |
| 58 | 15,058 | 1 |
| 59 | 15,285 | 1 |
| 60 | 16,206 | 1 |
| 61 | 16,269 | 1 |
| 62 | 166-175 | 1 |
| 63 | 21.0±3.8 | 1 |
| 64 | 21/89 | 1 |
| 65 | 22060 | 1 |
| 66 | 223,287 | 1 |
| 67 | 226,043 | 1 |
| 68 | 27/55 | 1 |
| 69 | 28,131 | 1 |
| 70 | 32,839 | 1 |
| 71 | 35,179 | 1 |
| 72 | 35,946 | 1 |
| 73 | 4,616 | 1 |
| 74 | 42,277 | 1 |
| 75 | 432747 | 1 |
| 76 | 5,042 | 1 |
| 77 | 51/455 | 1 |
| 78 | 5162 | 1 |
| 79 | 5299 | 1 |
| 80 | 5817 | 1 |
| 81 | 59,197 | 1 |
| 82 | 6,055 | 1 |
| 83 | 6,901 | 1 |
| 84 | 6-16-year-old | 1 |
| 85 | 61,590 | 1 |
| 86 | 62,154 | 1 |
| 87 | 68,150 | 1 |
| 88 | 68,402 | 1 |
| 89 | 71,463 | 1 |
| 90 | 736,536 | 1 |
| 91 | 7463 | 1 |
| 92 | 77,867 | 1 |
| 93 | 86/193 | 1 |
| 94 | 8857 | 1 |
| 95 | 8904 | 1 |
| 96 | 9,008 | 1 |
| 97 | 9,862 | 1 |
| 98 | 93,515 | 1 |
| 99 | 93,663 | 1 |
| 100 | 96,125 | 1 |
| 101 | 98,496 | 1 |
| 102 | ace-inhibitor-intolerant | 1 |
| 103 | act-treated | 1 |
| 104 | acute-on- | 1 |
| 105 | acute/decompensated | 1 |
| 106 | akt-negative | 1 |
| 107 | animals.from | 1 |
| 108 | anti-tnf-exposed | 1 |
| 109 | antihistamine-resistant | 1 |
| 110 | antiviral-naïve | 1 |
| 111 | aspirin-anticoagulant | 1 |
| 112 | atenolol-and | 1 |
| 113 | atp-treated | 1 |
| 114 | australian-qualified | 1 |
| 115 | automation-making | 1 |
| 116 | b*44:27-positive | 1 |
| 117 | barometeosensetiv | 1 |
| 118 | billing-reported | 1 |
| 119 | bio-converting | 1 |
| 120 | bis-alkylguanidine-based | 1 |
| 121 | bm-transplanted | 1 |
| 122 | borderline-status | 1 |
| 123 | caga-seropositive | 1 |
| 124 | cam-defined | 1 |
| 125 | cf-associated | 1 |
| 126 | childhood-abuse-related | 1 |
| 127 | ciclosporin-associated | 1 |
| 128 | clinically-monitored | 1 |
| 129 | co-cultural | 1 |
| 130 | coach-assisted | 1 |
| 131 | cocl2-simulating | 1 |
| 132 | coma.four | 1 |
| 133 | counselling-related | 1 |
| 134 | cpap-intolerant | 1 |
| 135 | cpf-treated | 1 |
| 136 | cryoglobulin-occlusive | 1 |
| 137 | cvb-triggered | 1 |
| 138 | dasatinib-treated | 1 |
| 139 | diabetes-independent | 1 |
| 140 | diary-documented | 1 |
| 141 | diethylpropion-treated | 1 |
| 142 | diuretic-resistant | 1 |
| 143 | dog-allergic | 1 |
| 144 | early-staged | 1 |
| 145 | eczema.in | 1 |
| 146 | eeg-proven | 1 |
| 147 | egfr-non-selected | 1 |
| 148 | er+/akt1+ | 1 |
| 149 | er+/akt1- | 1 |
| 150 | example-are | 1 |
| 151 | fcgr3a-v/v | 1 |
| 152 | femoro-patellar | 1 |
| 153 | first-salvage | 1 |
| 154 | high-consumption | 1 |
| 155 | hispanel-negative | 1 |
| 156 | hla-alloimmunized | 1 |
| 157 | hyperactive-type | 1 |
| 158 | hyperalgesia-induced | 1 |
| 159 | hyperglyceamic | 1 |
| 160 | ics-using | 1 |
| 161 | ifn-responding | 1 |
| 162 | ifnβ-1b-treated | 1 |
| 163 | iii°-iv° | 1 |
| 164 | il-11rα-based | 1 |
| 165 | il-17-associated | 1 |
| 166 | interferon-eligible | 1 |
| 167 | ish-associated | 1 |
| 168 | ka-treated | 1 |
| 169 | laboratory-characterized | 1 |
| 170 | ldl-r. | 1 |
| 171 | leptospirosis-associated | 1 |
| 172 | lighter-skinned | 1 |
| 173 | lithium-refractory | 1 |
| 174 | lvad-bridged | 1 |
| 175 | lysozyme-sensitized | 1 |
| 176 | maintenance-dialysis | 1 |
| 177 | mastectomy-only | 1 |
| 178 | mbt-treated | 1 |
| 179 | mcp-treated | 1 |
| 180 | microscopically-confirmed | 1 |
| 181 | moriz | 1 |
| 182 | mrna-screened | 1 |
| 183 | mstn-mediated | 1 |
| 184 | new-presentation | 1 |
| 185 | no-af | 1 |
| 186 | non-alerted | 1 |
| 187 | non-cevr | 1 |
| 188 | non-excluded | 1 |
| 189 | non-isat | 1 |
| 190 | non-subtyped | 1 |
| 191 | nonbiliary | 1 |
| 192 | nonconstipation | 1 |
| 193 | nonligated | 1 |
| 194 | norplant.although | 1 |
| 195 | not-responders | 1 |
| 196 | npm1-mutated | 1 |
| 197 | nucleoside/nucleotide-naïve | 1 |
| 198 | nucleotide-naive | 1 |
| 199 | paediatric-aged | 1 |
| 200 | palythoa | 1 |
| 201 | penicillinallergic | 1 |
| 202 | perk-mediated | 1 |
| 203 | pf-04447943-treated | 1 |
| 204 | phentermine-treated | 1 |
| 205 | placebo+mtx-treated | 1 |
| 206 | post-pvp | 1 |
| 207 | posteriorizing | 1 |
| 208 | prasugrel-mediated | 1 |
| 209 | present-oriented | 1 |
| 210 | presplenectomy | 1 |
| 211 | progestagen/equine | 1 |
| 212 | ptsd-level | 1 |
| 213 | qolin | 1 |
| 214 | r1441c/g/h-mediated | 1 |
| 215 | raping | 1 |
| 216 | relapsing- | 1 |
| 217 | remunerating | 1 |
| 218 | resistant/intolerant | 1 |
| 219 | risperidone-treatment | 1 |
| 220 | rs35599367cc | 1 |
| 221 | rsv-coded | 1 |
| 222 | scarler | 1 |
| 223 | seropositive-related | 1 |
| 224 | sertindole-treated | 1 |
| 225 | srs-treated | 1 |
| 226 | streptozotocyn-induced | 1 |
| 227 | stress-positive | 1 |
| 228 | stroke-threatened | 1 |
| 229 | suboxic | 1 |
| 230 | succesive | 1 |
| 231 | suining | 1 |
| 232 | surgery-ineligible | 1 |
| 233 | svr-eligible | 1 |
| 234 | t2-4/n0-2/m0 | 1 |
| 235 | tamoxifen-failed | 1 |
| 236 | tb-confirmed | 1 |
| 237 | tbs-treated | 1 |
| 238 | tch-treated | 1 |
| 239 | tensed | 1 |
| 240 | tetracycline-allergic | 1 |
| 241 | therapy-adherent | 1 |
| 242 | thoracic/thoracolumbar | 1 |
| 243 | tickle/cough | 1 |
| 244 | treatment-experience | 1 |
| 245 | tslp-driven | 1 |
| 246 | tzd-treated | 1 |
| 247 | uremic-associated | 1 |
| 248 | uri-associated | 1 |
| 249 | us-residing | 1 |
| 250 | vagus-controlled | 1 |
| 251 | volume-eater | 1 |
| 252 | younger/fitter | 1 |
| 253 | ypt0-2n+ | 1 |
| 254 | β-ar-mediated | 1 |
| 255 | β-hemoglobinopathy | 1 |
| 1 | 1,776 | 4 |
| 2 | 1,958,716 | 1 |
| 3 | 11,234 | 3 |
| 4 | 11,774 | 1 |
| 5 | 116/137 | 1 |
| 6 | 12,507 | 1 |
| 7 | 12,930 | 1 |
| 8 | 13,627 | 1 |
| 9 | 13107 | 1 |
| 10 | 14,209 | 1 |
| 11 | 14,754 | 1 |
| 12 | 146,961 | 1 |
| 13 | 15,058 | 1 |
| 14 | 15,285 | 1 |
| 15 | 15,847 | 2 |
| 16 | 16,206 | 1 |
| 17 | 16,269 | 1 |
| 18 | 166-175 | 1 |
| 19 | 21.0±3.8 | 1 |
| 20 | 21/89 | 1 |
| 21 | 22060 | 1 |
| 22 | 223,287 | 1 |
| 23 | 226,043 | 1 |
| 24 | 27/55 | 1 |
| 25 | 2778 | 2 |
| 26 | 28,131 | 1 |
| 27 | 3,204 | 2 |
| 28 | 32,839 | 1 |
| 29 | 35,179 | 1 |
| 30 | 35,946 | 1 |
| 31 | 4,589 | 2 |
| 32 | 4,616 | 1 |
| 33 | 42,277 | 1 |
| 34 | 432747 | 1 |
| 35 | 5,031 | 2 |
| 36 | 5,042 | 1 |
| 37 | 51/455 | 1 |
| 38 | 5162 | 1 |
| 39 | 5299 | 1 |
| 40 | 5474 | 2 |
| 41 | 5817 | 1 |
| 42 | 59,197 | 1 |
| 43 | 6,055 | 1 |
| 44 | 6,901 | 1 |
| 45 | 6-16-year-old | 1 |
| 46 | 61,590 | 1 |
| 47 | 62,154 | 1 |
| 48 | 68,150 | 1 |
| 49 | 68,402 | 1 |
| 50 | 7007 | 2 |
| 51 | 71,463 | 1 |
| 52 | 736,536 | 1 |
| 53 | 7463 | 1 |
| 54 | 77,867 | 1 |
| 55 | 86/193 | 1 |
| 56 | 8857 | 1 |
| 57 | 8904 | 1 |
| 58 | 9,008 | 1 |
| 59 | 9,862 | 1 |
| 60 | 93,515 | 1 |
| 61 | 93,663 | 1 |
| 62 | 96,125 | 1 |
| 63 | 98,496 | 1 |
| 64 | ace-inhibitor-intolerant | 1 |
| 65 | act-treated | 1 |
| 66 | acute-on- | 1 |
| 67 | acute/decompensated | 1 |
| 68 | akt-negative | 1 |
| 69 | animals.from | 1 |
| 70 | anthracycline-naïve | 2 |
| 71 | anti-tnf-exposed | 1 |
| 72 | anti-tnf-treated | 2 |
| 73 | antihistamine-resistant | 1 |
| 74 | antiviral-naïve | 1 |
| 75 | aspirin-anticoagulant | 1 |
| 76 | atenolol-and | 1 |
| 77 | atp-treated | 1 |
| 78 | australian-qualified | 1 |
| 79 | automation-making | 1 |
| 80 | b*44:27-positive | 1 |
| 81 | barometeosensetiv | 1 |
| 82 | billing-reported | 1 |
| 83 | bio-converting | 1 |
| 84 | bis-alkylguanidine-based | 1 |
| 85 | bm-transplanted | 1 |
| 86 | borderline-status | 1 |
| 87 | caf-treated | 2 |
| 88 | caga-seropositive | 1 |
| 89 | cam-defined | 1 |
| 90 | cf-associated | 1 |
| 91 | childhood-abuse-related | 1 |
| 92 | ciclosporin-associated | 1 |
| 93 | clinically-monitored | 1 |
| 94 | co-cultural | 1 |
| 95 | coach-assisted | 1 |
| 96 | cocl2-simulating | 1 |
| 97 | coma.four | 1 |
| 98 | counselling-related | 1 |
| 99 | cpap-intolerant | 1 |
| 100 | cpf-treated | 1 |
| 101 | cryoglobulin-occlusive | 1 |
| 102 | cvb-triggered | 1 |
| 103 | d2-dissected | 4 |
| 104 | dasatinib-treated | 1 |
| 105 | diabetes-independent | 1 |
| 106 | diary-documented | 1 |
| 107 | diethylpropion-treated | 1 |
| 108 | diuretic-resistant | 1 |
| 109 | dog-allergic | 1 |
| 110 | early-staged | 1 |
| 111 | eczema.in | 1 |
| 112 | eeg-proven | 1 |
| 113 | egfr-non-selected | 1 |
| 114 | endoscopy-refractory | 2 |
| 115 | er+/akt1+ | 1 |
| 116 | er+/akt1- | 1 |
| 117 | example-are | 1 |
| 118 | extubating | 4 |
| 119 | fcgr3a-v/v | 1 |
| 120 | femoro-patellar | 1 |
| 121 | first-salvage | 1 |
| 122 | flt3‑mutated | 2 |
| 123 | high-consumption | 1 |
| 124 | hispanel-negative | 1 |
| 125 | hla-alloimmunized | 1 |
| 126 | hs-fused | 2 |
| 127 | hyperactive-type | 1 |
| 128 | hyperalgesia-induced | 1 |
| 129 | hyperglyceamic | 1 |
| 130 | ics-using | 1 |
| 131 | ifn-responding | 1 |
| 132 | ifn-α-treated | 2 |
| 133 | ifnβ-1b-treated | 1 |
| 134 | iii°-iv° | 1 |
| 135 | il-11rα-based | 1 |
| 136 | il-17-associated | 1 |
| 137 | immunising | 5 |
| 138 | in-the-field | 2 |
| 139 | infection-confirmed | 2 |
| 140 | interferon-alpha-induced | 4 |
| 141 | interferon-eligible | 1 |
| 142 | ir-nmibc | 3 |
| 143 | ish-associated | 1 |
| 144 | ka-treated | 1 |
| 145 | laboratory-characterized | 1 |
| 146 | ldl-r. | 1 |
| 147 | leptospirosis-associated | 1 |
| 148 | lighter-skinned | 1 |
| 149 | lithium-refractory | 1 |
| 150 | lvad-bridged | 1 |
| 151 | lysozyme-sensitized | 1 |
| 152 | mad-treated | 2 |
| 153 | maintenance-dialysis | 1 |
| 154 | managing | 2,371 |
| 155 | mastectomy-only | 1 |
| 156 | mbt-treated | 1 |
| 157 | mcp-treated | 1 |
| 158 | microscopically-confirmed | 1 |
| 159 | middle-third | 6 |
| 160 | mixed-beam-treated | 2 |
| 161 | moriz | 1 |
| 162 | mrna-screened | 1 |
| 163 | mstn-mediated | 1 |
| 164 | multiple-drug-refractory | 2 |
| 165 | new-presentation | 1 |
| 166 | no-af | 1 |
| 167 | non-alerted | 1 |
| 168 | non-cevr | 1 |
| 169 | non-constipating | 2 |
| 170 | non-exacerbating | 2 |
| 171 | non-excluded | 1 |
| 172 | non-isat | 1 |
| 173 | non-subtyped | 1 |
| 174 | nonautoclaved | 2 |
| 175 | nonbiliary | 1 |
| 176 | nonconstipation | 1 |
| 177 | noninfection-related | 2 |
| 178 | nonligated | 1 |
| 179 | nonremitted | 3 |
| 180 | norplant.although | 1 |
| 181 | not-responders | 1 |
| 182 | npm1-mutated | 1 |
| 183 | nucleoside/nucleotide-naïve | 1 |
| 184 | nucleotide-naive | 1 |
| 185 | paediatric-aged | 1 |
| 186 | pain-predominant | 3 |
| 187 | palythoa | 1 |
| 188 | penicillinallergic | 1 |
| 189 | perceivably | 2 |
| 190 | perk-mediated | 1 |
| 191 | pf-04447943-treated | 1 |
| 192 | phentermine-treated | 1 |
| 193 | placebo+mtx-treated | 1 |
| 194 | pneumovirus-induced | 2 |
| 195 | post-pvp | 1 |
| 196 | posteriorizing | 1 |
| 197 | ppi-intolerant | 2 |
| 198 | prasugrel-mediated | 1 |
| 199 | present-oriented | 1 |
| 200 | presplenectomy | 1 |
| 201 | preventing/treating | 3 |
| 202 | progestagen/equine | 1 |
| 203 | ptsd-level | 1 |
| 204 | qolin | 1 |
| 205 | r1441c/g/h-mediated | 1 |
| 206 | raping | 1 |
| 207 | rehabilitating | 29 |
| 208 | relapsing- | 1 |
| 209 | remunerating | 1 |
| 210 | resistant/intolerant | 1 |
| 211 | risperidone-treatment | 1 |
| 212 | rs35599367cc | 1 |
| 213 | rsv-coded | 1 |
| 214 | salicylate-poisoned | 2 |
| 215 | scarler | 1 |
| 216 | seropositive-related | 1 |
| 217 | sertindole-treated | 1 |
| 218 | sri-refractory | 3 |
| 219 | srs-treated | 1 |
| 220 | streptozotocyn-induced | 1 |
| 221 | stress-positive | 1 |
| 222 | stroke-threatened | 1 |
| 223 | sub-typing | 2 |
| 224 | subacute/chronic | 21 |
| 225 | subclassifying | 3 |
| 226 | subdysthymic | 2 |
| 227 | suboxic | 1 |
| 228 | succesive | 1 |
| 229 | suining | 1 |
| 230 | surgery-ineligible | 1 |
| 231 | svr-eligible | 1 |
| 232 | t2-4/n0-2/m0 | 1 |
| 233 | tamoxifen-failed | 1 |
| 234 | tb-confirmed | 1 |
| 235 | tbs-treated | 1 |
| 236 | tch-treated | 1 |
| 237 | tensed | 1 |
| 238 | tetracycline-allergic | 1 |
| 239 | therapy-adherent | 1 |
| 240 | thoracic/thoracolumbar | 1 |
| 241 | tickle/cough | 1 |
| 242 | treating | 11,234 |
| 243 | treatment-experience | 1 |
| 244 | tslp-driven | 1 |
| 245 | tzd-treated | 1 |
| 246 | uremic-associated | 1 |
| 247 | uri-associated | 1 |
| 248 | us-residing | 1 |
| 249 | vagus-controlled | 1 |
| 250 | volume-eater | 1 |
| 251 | young/middle-aged | 4 |
| 252 | younger/fitter | 1 |
| 253 | ypt0-2n+ | 1 |
| 254 | β-ar-mediated | 1 |
| 255 | β-hemoglobinopathy | 1 |
| 1 | er+/akt1+ | 1 |
| 2 | ypt0-2n+ | 1 |
| 3 | er+/akt1- | 1 |
| 4 | relapsing- | 1 |
| 5 | acute-on- | 1 |
| 6 | ldl-r. | 1 |
| 7 | 12,930 | 1 |
| 8 | 68,150 | 1 |
| 9 | 22060 | 1 |
| 10 | 61,590 | 1 |
| 11 | t2-4/n0-2/m0 | 1 |
| 12 | 6,901 | 1 |
| 13 | 5,031 | 2 |
| 14 | 28,131 | 1 |
| 15 | 146,961 | 1 |
| 16 | 68,402 | 1 |
| 17 | 5,042 | 1 |
| 18 | 5162 | 1 |
| 19 | 9,862 | 1 |
| 20 | 226,043 | 1 |
| 21 | 71,463 | 1 |
| 22 | 7463 | 1 |
| 23 | 93,663 | 1 |
| 24 | 86/193 | 1 |
| 25 | 3,204 | 2 |
| 26 | 8904 | 1 |
| 27 | 11,234 | 3 |
| 28 | 62,154 | 1 |
| 29 | 14,754 | 1 |
| 30 | 5474 | 2 |
| 31 | 11,774 | 1 |
| 32 | 93,515 | 1 |
| 33 | 96,125 | 1 |
| 34 | 27/55 | 1 |
| 35 | 6,055 | 1 |
| 36 | 51/455 | 1 |
| 37 | 166-175 | 1 |
| 38 | 15,285 | 1 |
| 39 | 16,206 | 1 |
| 40 | 4,616 | 1 |
| 41 | 1,958,716 | 1 |
| 42 | 736,536 | 1 |
| 43 | 35,946 | 1 |
| 44 | 1,776 | 4 |
| 45 | 98,496 | 1 |
| 46 | 7007 | 2 |
| 47 | 13107 | 1 |
| 48 | 12,507 | 1 |
| 49 | 5817 | 1 |
| 50 | 13,627 | 1 |
| 51 | 116/137 | 1 |
| 52 | 432747 | 1 |
| 53 | 15,847 | 2 |
| 54 | 8857 | 1 |
| 55 | 77,867 | 1 |
| 56 | 42,277 | 1 |
| 57 | 223,287 | 1 |
| 58 | 59,197 | 1 |
| 59 | 21.0±3.8 | 1 |
| 60 | 9,008 | 1 |
| 61 | 15,058 | 1 |
| 62 | 2778 | 2 |
| 63 | 14,209 | 1 |
| 64 | 32,839 | 1 |
| 65 | 16,269 | 1 |
| 66 | 35,179 | 1 |
| 67 | 21/89 | 1 |
| 68 | 4,589 | 2 |
| 69 | 5299 | 1 |
| 70 | palythoa | 1 |
| 71 | ir-nmibc | 3 |
| 72 | rs35599367cc | 1 |
| 73 | tetracycline-allergic | 1 |
| 74 | dog-allergic | 1 |
| 75 | penicillinallergic | 1 |
| 76 | hyperglyceamic | 1 |
| 77 | subdysthymic | 2 |
| 78 | subacute/chronic | 21 |
| 79 | suboxic | 1 |
| 80 | interferon-alpha-induced | 4 |
| 81 | hyperalgesia-induced | 1 |
| 82 | streptozotocyn-induced | 1 |
| 83 | pneumovirus-induced | 2 |
| 84 | rsv-coded | 1 |
| 85 | non-excluded | 1 |
| 86 | paediatric-aged | 1 |
| 87 | young/middle-aged | 4 |
| 88 | early-staged | 1 |
| 89 | lvad-bridged | 1 |
| 90 | australian-qualified | 1 |
| 91 | tamoxifen-failed | 1 |
| 92 | vagus-controlled | 1 |
| 93 | tb-confirmed | 1 |
| 94 | infection-confirmed | 2 |
| 95 | microscopically-confirmed | 1 |
| 96 | mrna-screened | 1 |
| 97 | stroke-threatened | 1 |
| 98 | cam-defined | 1 |
| 99 | lighter-skinned | 1 |
| 100 | salicylate-poisoned | 2 |
| 101 | non-subtyped | 1 |
| 102 | cvb-triggered | 1 |
| 103 | clinically-monitored | 1 |
| 104 | bis-alkylguanidine-based | 1 |
| 105 | il-11rα-based | 1 |
| 106 | tensed | 1 |
| 107 | anti-tnf-exposed | 1 |
| 108 | hs-fused | 2 |
| 109 | pf-04447943-treated | 1 |
| 110 | ka-treated | 1 |
| 111 | ifnβ-1b-treated | 1 |
| 112 | dasatinib-treated | 1 |
| 113 | mad-treated | 2 |
| 114 | tzd-treated | 1 |
| 115 | sertindole-treated | 1 |
| 116 | phentermine-treated | 1 |
| 117 | caf-treated | 2 |
| 118 | anti-tnf-treated | 2 |
| 119 | cpf-treated | 1 |
| 120 | tch-treated | 1 |
| 121 | mixed-beam-treated | 2 |
| 122 | diethylpropion-treated | 1 |
| 123 | mcp-treated | 1 |
| 124 | atp-treated | 1 |
| 125 | tbs-treated | 1 |
| 126 | srs-treated | 1 |
| 127 | mbt-treated | 1 |
| 128 | act-treated | 1 |
| 129 | placebo+mtx-treated | 1 |
| 130 | ifn-α-treated | 2 |
| 131 | nonligated | 1 |
| 132 | il-17-associated | 1 |
| 133 | uremic-associated | 1 |
| 134 | cf-associated | 1 |
| 135 | ish-associated | 1 |
| 136 | uri-associated | 1 |
| 137 | ciclosporin-associated | 1 |
| 138 | leptospirosis-associated | 1 |
| 139 | r1441c/g/h-mediated | 1 |
| 140 | perk-mediated | 1 |
| 141 | prasugrel-mediated | 1 |
| 142 | mstn-mediated | 1 |
| 143 | β-ar-mediated | 1 |
| 144 | childhood-abuse-related | 1 |
| 145 | seropositive-related | 1 |
| 146 | counselling-related | 1 |
| 147 | noninfection-related | 2 |
| 148 | acute/decompensated | 1 |
| 149 | npm1-mutated | 1 |
| 150 | flt3‑mutated | 2 |
| 151 | egfr-non-selected | 1 |
| 152 | d2-dissected | 4 |
| 153 | bm-transplanted | 1 |
| 154 | present-oriented | 1 |
| 155 | diary-documented | 1 |
| 156 | non-alerted | 1 |
| 157 | billing-reported | 1 |
| 158 | coach-assisted | 1 |
| 159 | nonremitted | 3 |
| 160 | nonautoclaved | 2 |
| 161 | hla-alloimmunized | 1 |
| 162 | laboratory-characterized | 1 |
| 163 | lysozyme-sensitized | 1 |
| 164 | in-the-field | 2 |
| 165 | 6-16-year-old | 1 |
| 166 | atenolol-and | 1 |
| 167 | middle-third | 6 |
| 168 | treatment-experience | 1 |
| 169 | first-salvage | 1 |
| 170 | interferon-eligible | 1 |
| 171 | svr-eligible | 1 |
| 172 | surgery-ineligible | 1 |
| 173 | progestagen/equine | 1 |
| 174 | hyperactive-type | 1 |
| 175 | example-are | 1 |
| 176 | nucleotide-naive | 1 |
| 177 | succesive | 1 |
| 178 | cryoglobulin-occlusive | 1 |
| 179 | hispanel-negative | 1 |
| 180 | akt-negative | 1 |
| 181 | b*44:27-positive | 1 |
| 182 | stress-positive | 1 |
| 183 | caga-seropositive | 1 |
| 184 | nucleoside/nucleotide-naïve | 1 |
| 185 | anthracycline-naïve | 2 |
| 186 | antiviral-naïve | 1 |
| 187 | no-af | 1 |
| 188 | us-residing | 1 |
| 189 | ifn-responding | 1 |
| 190 | managing | 2,371 |
| 191 | automation-making | 1 |
| 192 | suining | 1 |
| 193 | raping | 1 |
| 194 | sub-typing | 2 |
| 195 | immunising | 5 |
| 196 | ics-using | 1 |
| 197 | non-exacerbating | 2 |
| 198 | extubating | 4 |
| 199 | treating | 11,234 |
| 200 | preventing/treating | 3 |
| 201 | cocl2-simulating | 1 |
| 202 | non-constipating | 2 |
| 203 | remunerating | 1 |
| 204 | rehabilitating | 29 |
| 205 | bio-converting | 1 |
| 206 | subclassifying | 3 |
| 207 | posteriorizing | 1 |
| 208 | tickle/cough | 1 |
| 209 | norplant.although | 1 |
| 210 | co-cultural | 1 |
| 211 | ptsd-level | 1 |
| 212 | animals.from | 1 |
| 213 | tslp-driven | 1 |
| 214 | eeg-proven | 1 |
| 215 | eczema.in | 1 |
| 216 | qolin | 1 |
| 217 | nonconstipation | 1 |
| 218 | new-presentation | 1 |
| 219 | high-consumption | 1 |
| 220 | post-pvp | 1 |
| 221 | thoracic/thoracolumbar | 1 |
| 222 | femoro-patellar | 1 |
| 223 | scarler | 1 |
| 224 | volume-eater | 1 |
| 225 | younger/fitter | 1 |
| 226 | coma.four | 1 |
| 227 | non-cevr | 1 |
| 228 | maintenance-dialysis | 1 |
| 229 | not-responders | 1 |
| 230 | borderline-status | 1 |
| 231 | non-isat | 1 |
| 232 | aspirin-anticoagulant | 1 |
| 233 | pain-predominant | 3 |
| 234 | ppi-intolerant | 2 |
| 235 | cpap-intolerant | 1 |
| 236 | ace-inhibitor-intolerant | 1 |
| 237 | resistant/intolerant | 1 |
| 238 | diuretic-resistant | 1 |
| 239 | antihistamine-resistant | 1 |
| 240 | diabetes-independent | 1 |
| 241 | risperidone-treatment | 1 |
| 242 | therapy-adherent | 1 |
| 243 | fcgr3a-v/v | 1 |
| 244 | barometeosensetiv | 1 |
| 245 | β-hemoglobinopathy | 1 |
| 246 | perceivably | 2 |
| 247 | mastectomy-only | 1 |
| 248 | presplenectomy | 1 |
| 249 | nonbiliary | 1 |
| 250 | multiple-drug-refractory | 2 |
| 251 | sri-refractory | 3 |
| 252 | lithium-refractory | 1 |
| 253 | endoscopy-refractory | 2 |
| 254 | moriz | 1 |
| 255 | iii°-iv° | 1 |